Gland Pharma Ltd
Gland Pharma Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Base business (ex-Cenexi) revenue declined 8% YoY in Q3 FY'25 due to volume de-growth in key products but is expected to recover volumes in coming quarters. - U.S. EBITDA margins expected to improve beyond past levels of 33%-34%, reflecting better product mix and new product launches (Ravi Mitra, Page 15). - Base business excluding Cenexi showed strong EBITDA margin improvement to 39% from 34% YoY, driven by product mix and cost control (Page 7). - Cenexi expects positive EBITDA by full year FY 2026, with revenue targets beyond EUR 200 million, despite recent quarter challenges (Alain Kirchmeyer, Page 6). - New capacity additions at Cenexi (new ampoule and prefilled syringe lines) to boost production and support growth (Page 6). - Launch of 13 new molecules in the U.S.
From Gland Pharma Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Base business (ex-Cenexi) revenue declined 8% YoY in Q3 FY'25 due to volume de-growth in key products but is expected to recover volumes in coming quarters.
- U.S. sales strengthened with 13 new molecule launches, enhancing portfolio for growth.
- Enoxa volumes are expected to increase, although higher Enoxa volumes may slightly reduce overall margins.
- New launches (complex generics, RTUs) with higher gross margins (~65%) are being aggressively pushed to sustain/improve margins.
- New auto injector line adding 100 million capacity expected to contribute mainly from end FY'27, with smaller volumes from FY'26.
- Cenexi business expected to reach EBITDA breakeven by Q3 FY'26 with new high-speed lines and cost controls.
- Focus on expanding presence in key RoW markets (top 5-6 countries) with aggressive partnerships and filings.
2 more points from Gland Pharma Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Gland Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Adding one more pen/auto injector assembly line this year, adding 100 million capacity; most of the capex already spent; commissioning expected by FY '28 (major volumes end FY '27).
- Evaluating biosimilars capacity expansion (~15 KL), estimated capex $80-$100 million; process of project evaluation ongoing.
- GLP-1 line investment mostly done; line to be installed within next 2 quarters; planning a greenfield project for next growth phase.
- Cartridge capacity expansion: new cartridge line addition at Suite 9 in India in progress alongside existing line.
- At Cenexi (France), installing new high-speed ampoule and prefilled syringe lines to improve capacity and capabilities.
2 more points from Gland Pharma Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gland Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The current order book for the fourth quarter is approximately EUR 60 million, carrying over backlog from 2024. (Page 17)
- Cenexi typically maintains a 3-month confirmed order horizon with customers. (Page 17)
- There's a pipeline of RFPs being addressed, with recent validation batches for 2 products moving into commercial production in Q1. (Page 14)
- Some contracts and shipments, such as the Saudi contract, have faced delays, with expected progress in Q4 or early next year. (Page 9)
2 more points from Gland Pharma Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Gland Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.7K Cr, net profit ₹367 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gland Pharma Ltd's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Gland Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gland Pharma Ltd Q3 FY25 results?
Base business (ex-Cenexi) revenue declined 8% YoY in Q3 FY'25 due to volume de-growth in key products but is expected to recover volumes in coming quarters. - U.S. EBITDA margins expected to improve beyond past levels of 33%-34%, reflecting better product mix and new product launches (Ravi Mitra, Page 15). - Base business excluding Cenexi showed strong EBITDA margin improvement to 39% from 34% YoY, driven by product mix and cost control (Page 7). - Cenexi expects positive EBITDA by full year FY 2026, with revenue targets beyond EUR 200 million, despite recent quarter challenges (Alain Kirchmeyer, Page 6). - New capacity additions at Cenexi (new ampoule and prefilled syringe lines) to boost production and support growth (Page 6). - Launch of 13 new molecules in the U.S.
What is Gland Pharma Ltd share price analysis?
Gland Pharma Ltd currently shows a neutral. The stock trades at a P/E of 42.8 with a market cap of ₹48,998 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gland Pharma Ltd planning capital expenditure?
Adding one more pen/auto injector assembly line this year, adding 100 million capacity; most of the capex already spent; commissioning expected by FY '28 (major volumes end FY '27).
Keep Gland Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.